|
VPS54 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.99130001377057E-09 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.62458935193399E-12 |
| Stage1-vs-Stage2 |
7.057800E-01 |
| Stage1-vs-Stage3 |
3.295600E-02 |
| Stage1-vs-Stage4 |
5.877000E-03 |
| Stage2-vs-Stage3 |
7.196300E-02 |
| Stage2-vs-Stage4 |
2.425800E-02 |
| Stage3-vs-Stage4 |
4.807800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.0364000000429E-06 |
| Normal-vs-Asian |
5.88270543389058E-11 |
| Caucasian-vs-AfricanAmerican |
1.607600E-01 |
| Caucasian-vs-Asian |
2.341000E-01 |
| AfricanAmerican-vs-Asian |
6.190200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.653400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(81-100Yrs) |
1.44950000002808E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.907000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.698600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.972410E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.288200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.673600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.022800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.85089999952204E-07 |
| Classical-VS-Follicular |
2.928200E-02 |
| Classical-VS-Other |
9.039000E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
7.65190000251437E-08 |
| Tall-VS-Other |
6.422400E-03 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.006600E-01 |
| Follicular-VS-Normal |
7.96919999990209E-08 |
| Other-VS-Normal |
5.647500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.60902410786912E-14 |
| N0-vs-N1 |
1.898020E-01 |
|
|
